Abstract 803: A spatial profiling approach to evaluating the prognostic impact of heterogeneity in the triple-negative breast cancer immune microenvironment.

Abstract Triple-negative breast cancer (TNBC), the breast cancer subtype defined by the absence of hormone receptors and no amplified HER2 receptors, is the most aggressive breast cancer subtype. Targeted treatment remains a challenge with TNBC. Non-targeted chemotherapy regimens have been the longstanding treatment modality, recently supplemented by immune checkpoint inhibitors (ICIs) targeting the PD-1/PDL1 pathway. TNBC’s high tumor mutational burden, PD-1 expression, and immunogenicity make it a good candidate for immunotherapy. However, further studies are needed to determine the individuals that benefit most from this treatment. Factors like the spatial patterns of immune cell infiltration, immune-tumour cell and immune-immune cell relationships impact the immune microenvironment’s anti-tumour response and ICI response. The high-plex spatial analysis of archival patient tissue samples—an abundant but underutilised resource for tumor characterization—has remained a challenge. However, using the GeoMx Digital Spatial Profiler (DSP), the spatial immune heterogeneity of 40 immune markers were quantified in a cohort of archival treatment-naïve TNBC tumours (n=140). The heterogeneity of 40 immune markers identifying immune cell lineages and sub lineages, activation and exhaustion states was quantified across separate stromal spatial regions of immune infiltration (n=486 from 140 patients). Tumours with overall low immune cell infiltration were significantly associated with higher spatial immune heterogeneity. Notably, low immune infiltration was also associated with a significantly higher spatial immune heterogeneity and total expression of multiple immunosuppressive markers, some of which are ICI targets This suggests that immunosuppression is spatially localized in stromal niches, which would impact immunotherapy response. High spatial immune heterogeneity was also associated with a trend of poorer patient survival. Citation Format: Prerana Sensharma, Huidan Zuo, Melanie Dawe, Megan Hopkins, Zeynep Baskurt, Osvaldo Espin-Garcia, Philippe L. Bedard, Melanie Spears, Susan J. Done. A spatial profiling approach to evaluating the prognostic impact of heterogeneity in the triple-negative breast cancer immune microenvironment [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 803.

Authors

Institutions

Publication Details

Journal
Cancer Research
Published
2026-04-03
DOI
https://doi.org/10.1158/1538-7445.am2026-803
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 803: A spatial profiling approach to evaluating the prognostic impact of heterogeneity in the triple-negative breast cancer immune microenvironment.

Susan J. Done, Melanie Spears, Philippe Lucien Bedard, Prerana Sensharma et al.
Cancer Research
Cancer Immunotherapy and Biomarkers
article

Abstract 803: A spatial profiling approach to evaluating the prognostic impact of heterogeneity in the triple-negative breast cancer immune microenvironment.

Susan J. Done, Melanie Spears, Philippe Lucien Bedard, Prerana Sensharma, Zeynep Baskurt, Melanie Dawe, Osvaldo Espin-Garcia, Megan Hopkins, Huidan Zuo
article en

Abstract

Abstract Triple-negative breast cancer (TNBC), the breast cancer subtype defined by the absence of hormone receptors and no amplified HER2 receptors, is the most aggressive breast cancer subtype. Targeted treatment remains a challenge with TNBC. Non-targeted chemotherapy regimens have been the longstanding treatment modality, recently supplemented by immune checkpoint inhibitors (ICIs) targeting the PD-1/PDL1 pathway. TNBC’s high tumor mutational burden, PD-1 expression, and immunogenicity make it a good candidate for immunotherapy. However, further studies are needed to determine the individuals that benefit most from this treatment. Factors like the spatial patterns of immune cell infiltration, immune-tumour cell and immune-immune cell relationships impact the immune microenvironment’s anti-tumour response and ICI response. The high-plex spatial analysis of archival patient tissue samples—an abundant but underutilised resource for tumor characterization—has remained a challenge. However, using the GeoMx Digital Spatial Profiler (DSP), the spatial immune heterogeneity of 40 immune markers were quantified in a cohort of archival treatment-naïve TNBC tumours (n=140). The heterogeneity of 40 immune markers identifying immune cell lineages and sub lineages, activation and exhaustion states was quantified across separate stromal spatial regions of immune infiltration (n=486 from 140 patients). Tumours with overall low immune cell infiltration were significantly associated with higher spatial immune heterogeneity. Notably, low immune infiltration was also associated with a significantly higher spatial immune heterogeneity and total expression of multiple immunosuppressive markers, some of which are ICI targets This suggests that immunosuppression is spatially localized in stromal niches, which would impact immunotherapy response. High spatial immune heterogeneity was also associated with a trend of poorer patient survival. Citation Format: Prerana Sensharma, Huidan Zuo, Melanie Dawe, Megan Hopkins, Zeynep Baskurt, Osvaldo Espin-Garcia, Philippe L. Bedard, Melanie Spears, Susan J. Done. A spatial profiling approach to evaluating the prognostic impact of heterogeneity in the triple-negative breast cancer immune microenvironment [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 803.

Cancer ResearchVol. 86(7_Supplement)
Ontario Institute for Cancer Research (CA), University of Toronto (CA), Toronto General Hospital (CA), Princess Margaret Cancer Centre (CA)
No poverty
Openalex Percentile: Top 33%
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.